Protein platforms revenues grew 21 percent, while biotechnology revenues were up 18 percent, and diagnostic revenues increased 2 percent.
Exosome markets a urine-based test called ExoDx Prostate (IntelliScore) to help determine whether patients with ambiguous PSA tests needs a prostate biopsy.
Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.
The company has highlighted the study as evidence that its test would outperform Roche's FDA-approved liquid biopsy assay if implemented in the clinic.
The company will design and validate a test using its Exolution isolation kit, which can stratify and monitor patients in Intezyne's clinical trials of IT-139.
Based on technology developed at Mass General, the platform will allow the company and its customers to add protein detection to nucleic acid analysis.
The coverage decision is based on the results of an evidence development study the companies launched last year.
A research collaboration involving several universities has yielded a technique that they said isolates exosomes from biological samples more effectively than incumbent methods.
The study is part of an effort to drive health plan coverage for Exosome's ExoDx Prostate IntelliScore prostate cancer test.
Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.
NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.
A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.
In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.